MAIA Biotechnology's 2025 Highlights and 2026 Milestones for Ateganosine in Non-Small Cell Lung Cancer Treatment

MAIA Biotechnology's lead drug, Ateganosine, has shown a median overall survival of 17.8 months in a Phase 2 clinical trial for non-small cell lung cancer. The FDA has granted Fast Track designation for Ateganosine, and the Phase 3 trial is ongoing. MAIA plans to conclude Part C of the Phase 2 study and start Phase 1 trials for other in-house-developed small molecules in 2026.